Ask AI
ProCE Banner Activity

ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer

Conference Coverage
Podcast

In this podcast, experts review 2 of the most important studies presented at the ASCO 2026 annual conference that inform treatment decisions for patients with early-stage hormone receptor–positive/HER2-negative breast cancer. The discussion focuses on the phase III OPTIMA trial, which evaluated Prosigna PAM50-guided chemotherapy selection and the potential for chemotherapy de-escalation in selected patients, with stimulating insights on the role of ovarian function suppression with endocrine therapy in premenopausal women. Their discussion also examines the NATALEE PAM50 biomarker analysis, which demonstrated benefit from adjuvant ribociclib across intrinsic molecular breast cancer subtypes without a significant treatment-by-subtype interaction. Together, these findings help clarify how genomic risk assessment, menopausal status, tumor biology, and adjuvant CDK4/6 inhibitor therapy may be integrated into individualized treatment planning and shared decision-making.

Released: September 08, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Lilly and Stemline Therapeutics, Inc.

Lilly

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with various forms of breast cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from breast cancer studies at ASCO 2026 and expert guidance to optimize personalized breast cancer care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify breast cancer patients most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for breast cancer to accelerate their effective incorporation into clinical practice

Financial Disclosures

Primary Author

Nerea Lopetegui-Lia, MD: advisor: Daiichi Sankyo, Pfizer.

Hope S. Rugo, MD, FASCO: consultant/advisor/speaker: BioNTech, Bristol Myers Squibb, Helsinn, Napo; researcher (paid to institution): ALX Oncology, Ambryx, AstraZeneca, Bicycle, Daiichi Sankyo, F. Hoffmann-La Roche/Genentech, Gilead Sciences, Lilly, Mabwell, Merck, Novartis, Pfizer, PhoenixMD, Relay, Stemline.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.